原標(biāo)題：對(duì)貓進(jìn)行免疫，以誘導(dǎo)針對(duì)人類主要貓過(guò)敏原Fel d1的中和抗體
　?、偃祟悓?duì)貓的過(guò)敏通常是由貓的主要過(guò)敏原Fel d1引起的，約10%的西方人群中存在貓過(guò)敏。目前，沒(méi)有治療貓過(guò)敏的有效和安全方法。過(guò)敏患者通常的應(yīng)對(duì)方法是盡量避免和貓的接觸或治療他們的過(guò)敏癥狀。②我們開(kāi)發(fā)了一種新的策略，用自身主要過(guò)敏原Fel d1對(duì)貓進(jìn)行免疫，來(lái)治療人類受試者由Fel d1引起的過(guò)敏。③采用重組Fel d 1與來(lái)源于黃瓜花葉病毒的病毒樣顆粒組成的聯(lián)合疫苗對(duì)貓進(jìn)行免疫【黃瓜花葉病毒含有破傷風(fēng)毒素衍生的通用T細(xì)胞表位tt830-843 (CuMVTT)】。首次單獨(dú)或聯(lián)合使用Fel-CuMVTT疫苗進(jìn)行耐受性和免疫原性研究，包括增量注射。④該疫苗耐受性良好，沒(méi)有明顯的毒性作用。所有的貓都能誘導(dǎo)出強(qiáng)而持久的特異性IgG抗體反應(yīng)。誘導(dǎo)的抗fel d1抗體具有較高的親和力，在體內(nèi)外均表現(xiàn)出較強(qiáng)的中和能力。內(nèi)源性變應(yīng)原水平降低，淚液樣本的變應(yīng)原性降低。⑤給貓接種Fel-CuMVTT可以誘導(dǎo)中和抗體，并可能減少貓主人的過(guò)敏癥狀。人類受試者和動(dòng)物都可以從這種治療中獲益，因?yàn)檫^(guò)敏的貓主人可以降低患慢性疾病(如哮喘)的風(fēng)險(xiǎn)，并變得更能容忍他們的貓，因此這些貓可以呆在家里，不需要被送到動(dòng)物收容所。


延伸閱讀
JACI
Immunization of cats to induce neutralizing antibodies against Fel d 1, the major feline allergen in human subjects
DOI: https://doi.org/10.1016/j.jaci.2019.01.050
Background
Cat allergy in human subjects is usually caused by the major cat allergen Fel d 1 and is found in approximately 10% of the Western population. Currently, there is no efficient and safe therapy for cat allergy available. Allergic patients usually try to avoid cats or treat their allergy symptoms.
Objective
We developed a new strategy to treat Fel d 1–induced allergy in human subjects by immunizing cats against their own major allergen, Fel d 1.
Methods
A conjugate vaccine consisting of recombinant Fel d 1 and a virus-like particle derived from the cucumber mosaic virus containing the tetanus toxin–derived universal T-cell epitope tt830-843 (CuMVTT) was used to immunize cats. A first tolerability and immunogenicity study, including a boost injection, was conducted by using the Fel-CuMVTT vaccine alone or in combination with an adjuvant.
Results
The vaccine was well tolerated and had no overt toxic effect. All cats induced a strong and sustained specific IgG antibody response. The induced anti–Fel d 1 antibodies were of high affinity and exhibited a strong neutralization ability tested both in vitro and in vivo. A reduction in the endogenous allergen level and a reduced allergenicity of tear samples, were observed.
Conclusion
Vaccination of cats with Fel-CuMVTT induces neutralizing antibodies and might result in reduced symptoms of allergic cat owners. Both human subjects and animals could profit from this treatment because allergic cat owners would reduce their risk of developing chronic diseases, such as asthma, and become more tolerant of their cats, which therefore could stay in the households and not need to be relinquished to animal shelters
All Author:
Franziska Thoms , Peter Hunziker Melanie Maudrich Gary T. Jennings Monique Vogel Stefanie Haas Andris Zeltins Regina Hofmann-Lehmann Barbara Riond Jonas Grossmann
Antonia Fettelschoss-Gabriel Gabriela Sen Thomas M. Kündig Martin F. BachmannxMartin
　　創(chuàng)建過(guò)敏性疾病的科研、科普知識(shí)交流平臺(tái)，為過(guò)敏患者提供專業(yè)診斷、治療、預(yù)防的共享平臺(tái)。